Rallybio Files Prospectus Related To Disposition From Time To Time Of Up To 3.6M Shares Of Common Stock By Selling Stockholder
$RLYB
Biotechnology: Pharmaceutical Preparations
Health Care
-SEC Filing
-SEC Filing
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Overweight → Neutral | JP Morgan | |
| 2/7/2024 | $7.00 → $1.50 | Buy → Hold | Jefferies |
| 4/17/2023 | $18.00 | Buy | H.C. Wainwright |
| 4/10/2023 | $17.00 | Outperform | Wedbush |
| 12/9/2022 | $21.00 | Overweight | JP Morgan |
| 2/22/2022 | $32.00 | Mkt Outperform | JMP Securities |
| 8/23/2021 | $40.00 | Outperform | Evercore ISI Group |
| 8/23/2021 | Outperform | Cowen |
-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place on Monday, December 2 at 8:30 AM Eastern Time and will review recent manufacturing process enhancements, biomarker characterization analyses, and the Company
— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Screening is now underway to identify the first (sentinel) pregnant woman for enrollment in the Phase 2 trial. "The initiation of screening in the RLYB212 Phase 2 trial is a significant milestone," s
— CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 — — $75.1 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2024 Provides Runway into Mid-2026 — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported third quarter financial results for the period ended September 30, 2024, and provided an update on recent company developments. "Advancing RLYB212 into a Phase 2 trial marks a significant achievement for Rallybio. With clinical trial application (CTA) approvals in-han
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea
– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries –– Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the RLYB212 Addressable Market –– Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Study in Pregnant Women at Higher Risk for FNAIT in 2H 2024 –Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported topline results from an epidemiological analysis of large genomic datasets evaluating the frequency of fetal and neonatal alloimm
Gainers Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 8.58% to $2.15. The market value of their outstanding shares is at $3.1 million. Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 8.27% to $0.59. The market value of their outstanding shares is at $6.0 million. Kiora Pharmaceuticals (NASDAQ:KPRX) shares rose 5.0% to $0.45. The market value of their outstanding shares is at $11.9 million. Fractyl Health (NASDAQ:GUTS) shares moved upwards by 4.94% to $6.79. The market value of their outstanding shares is at
JP Morgan analyst Anupam Rama downgrades Rallybio (NASDAQ:RLYB) from Overweight to Neutral.
10-Q - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
JP Morgan downgraded Rallybio from Overweight to Neutral
Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously
H.C. Wainwright initiated coverage of Rallybio with a rating of Buy and set a new price target of $18.00
-- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart
-- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)